Sign in / Join Now
ETFs & Funds
Chart Watch: We added $
to our long plays @ 37.00. Looks good over $37. Tgt 37.70, 39.30.
Add a reply...
Latest StockTalks »
people get BMY breaking news and analysis by email alert.
Get email alerts on BMY »
Bristol-Myers Squibb Company
Get latest price
From other sites
Encouraging Survival Observed With Opdivo (nivolumab) Plus Yervoy (ipilimumab) With Longer Follow-up In First-line Advanced Non-small Cell Lung Cancer, In Updated Phase 1b CheckMate -012 Study
at TheStreet (Mon, 5:00AM)
Bristol-Myers Squibb To Take Part At The Citi 2016 Global Healthcare Conference
at TheStreet (Wed, 9:54AM)
Bristol-Myers Squibb, Cerner, General Motors, Monsanto: Fast Money Picks For November 25
at Benzinga (Nov 25, 2016)
European Commission Approves Bristol-Myers Squibb's Opdivo (nivolumab) For The Treatment Of Adult Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant And Treatment With Brentuximab Vedotin
at TheStreet (Nov 22, 2016)
Bristol-Myers Squibb Presents New Data At IASLC 17th World Conference On Lung Cancer Underscoring Progress And Leadership In Broad Lung Development Program
at TheStreet (Nov 16, 2016)